Comparing SEER and NCDB: a case study using colorectal cancer
Cancer Causes & Control · 2024
DOI: 10.1007/s10552-024-01902-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Causes & Control, 2024. Verfasst von Po-Hong Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Suite 520U,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, SEER Program. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Suite 520U, Dallas, TX, 75235, USA. stuartliu@gmail.com.
- Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Suite 520U, Dallas, TX, 75235, USA.
- School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
Förderung
- National Institutes of Health
Zitieren
APA
Liu, P. H., Pruitt, S. L., Singal, A. G., & Murphy, C. C. (2024). Comparing SEER and NCDB: a case study using colorectal cancer. Cancer Causes & Control. https://doi.org/10.1007/s10552-024-01902-3
Vancouver
Liu PH, Pruitt SL, Singal AG, Murphy CC. Comparing SEER and NCDB: a case study using colorectal cancer. Cancer Causes & Control. 2024. doi:10.1007/s10552-024-01902-3
BibTeX
@article{Liu2024,
author = {Liu, Po-Hong and Pruitt, Sandi L and Singal, Amit G and Murphy, Caitlin C},
title = {Comparing SEER and NCDB: a case study using colorectal cancer},
journal = {Cancer Causes & Control},
year = {2024},
doi = {10.1007/s10552-024-01902-3}
}
EUVIMED